Oncology & Cancer

Biomarker predicts resistance to immunotherapies in melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system ...


FDA approves drug combo for metastatic non-small cell lung cancer

The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing ...


Improving drug therapy for relapsed leukemia

A combination of two drugs showed promise in treating relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, according to a Northwestern Medicine study published ...

page 1 from 5